Table 1.
Characteristics of the studies used to develop the database
| Study | Ref.1 | Sex2 | Breeds3 | Additives (doses, mg/kg DM)4 | n | DOF | iBW | fBW |
|---|---|---|---|---|---|---|---|---|
| 1 | A | ST | AN, HE, ANxHE | C, VM (10, 25, 50) | 790 | 245 | 217 | 477 |
| 2 | A | ST | ANxHE | C, VM (6.6, 8.9, 13.6) | 190 | 109 | 390 | 586 |
| 3 | A | ST | BR | C, VM (11, 19.3, 27.6) | 280 | 168 | 301 | 521 |
| 4 | A | ST | HE, CHxHExSH | C, VM (11, 19.3, 27.6) | 395 | 141 | 341 | 509 |
| 5 | A | ST/HF | CH, CHx/ANx, HEx, LIx, BRx, SIx | C, VM (11, 19.3, 27.6) | 399 | 120 | 325 | 504 |
| 6 | B | ST | ANx, HEx, LIx, BRx, SIx | C, VM (11, 19.3, 27.6) | 318 | 141 | 313 | 545 |
| 7 | C | ST | AN, HE, ANxHE | C, VM (27.6), MO (27.6) | 240 | 128 | 344 | 525 |
| 8 | C | ST | HE | C, VM (19.3, 27.6), MO (27.6) | 387 | 139 | 321 | 550 |
| 9 | C | ST | AN, HE, ANxHE | C, VM (19.3, 27.6), MO (27.6) | 318 | 138 | 352 | 561 |
| 10 | D | St | ANx, HEx, LIx, BRx, SIx | C, VM (19.3, 20), MO (27.6) | 312 | 156 | 332 | 540 |
| 11 | C | ST | BR | C, VM (23.7), MO (33.8) | 298 | 123 | 361 | 589 |
| 12 | C | ST | ANxHE | C, VM (19.3), MO (27.6) | 297 | 128 | 341 | 570 |
| 13 | C | ST | ANx, HEx, CHx, SIx | C, VM (24.5), MO (27.1) | 297 | 130 | 302 | 558 |
| 14 | C | ST | HEx, SAx,CHx | C, VM (19.3), MO (30.6) | 295 | 111 | 373 | 599 |
| 15 | A | ST | HE | C, VM (11, 19.3, 27.6), MO (27.6) | 393 | 134 | 310 | 479 |
| 16 | E | ST | ANxHE | C, VM (11, 19.3), MO (27.6) | 221 | 140 | 338 | 566 |
| 17 | C | ST | AN, ANxHE | C, VM (11, 19.3), MO (27.6) | 254 | 118 | 362 | 566 |
| 18 | F | ST | ANxHE | C, VM (11), MO (27.6) | 200 | 133 | 350 | 585 |
| 19 | G | BU | FR | C, VM (0, 20, 25, 40, 50) | 133 | 119 | 251 | 410 |
| 20 | H | ST | HO | C, VM (16, 22.5), MO (28) | 144 | 340 | 119 | 590 |
| 21 | I | ST | HExBR, ANxBR, SHxBR, CHxBR | C, VM (26), MO (34) | 135 | 143 | 314 | 552 |
| 22 | J | ST | HO | C, VM (22.5) | 120 | 308 | 131 | 575 |
| 23 | K | BU | NE | VM (25), MO (30) | 100 | 101 | 392 | 538 |
| 24 | L | ST | ND | C, VM (28) | 80 | 152 | 298 | 527 |
| 25 | M | ST | ND | C, VM (22.7) | 80 | 342 | 131 | 623 |
| 26 | N | ST/HF | ND | C, VM (20) | 480 | 152 | 448 | 668 |
n = number of animals in the study; DOF = days on feed; iBW = initial BW, kg; fBW = final BW, kg.
1References: A = Rogers et al. (1995) and SmithKline V-Max Technical Manual; B = Smith et al. (1989), Rogers et al. (1995), and SmithKline V-Max Technical Manual; C = SmithKline V-Max Technical Manual; D = Bartle et al. (1991) and SmithKline V-Max Technical Manual; E = Gill et al. (1990) and SmithKline V-Max Technical Manual; F = Gill et al. (1989) and SmithKline V-Max Technical Manual; G = Parigi-Bini (1979); H = Salinas-Chavira et al. (2009); I = Montano et al. (2014); J = Salinas-Chavira et al. (2016); K = Lemos et al. (2016); L = Navarrete et al. (2017); M = Richard A. Zinn (personal communication); and N = Jim et al. (2017).
2BU = bulls; HF = heifers; ST = steers.
3AN = Angus; BR = Brahman; CH = Charolais; FR = Friesian; HE = Hereford; LI = Limousin; NE = Nellore; SA = Salers; SH = Shorthorn; SI = Simmental; ND = not defined (most likely crossbreds).
4C = control; MO = monensin + tylosin; VM = virginiamycin. Studies may contain additional treatments not listed in this table.